Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Sarcoma, Kaposi: early-phase trial registry

A small indexed set (6 trials) with no open enrollment listed right now.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · none currently recruiting · #2,866 of 28,707 conditions by registered trial count

Sarcoma, Kaposi: 6 US clinical trials tracked, none currently recruiting.

Sarcoma, Kaposi is the subject of 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 4 of these trials.

Enrollment posture brief

Registry condition sarcoma-kaposi

OPEN 0 | RECR 0% | LATE 1 | EARLY 4 | RANK #2866 | SPON 4

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Sarcoma, Kaposi (this)0%
Open-enrollment share among volume-matched conditions near Sarcoma, Kaposi

Sarcoma, Kaposi has no open enrollment in this registry pull (6 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Sarcoma, Kaposi on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Sarcoma, Kaposi is recruiting below its size-band peers.

    0 of 6 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Sarcoma, Kaposi research.

    National Institute of Allergy and Infectious Diseases (NIAID) accounts for 4 of 6 trials (66.7%). 3 distinct sponsors appear on at least one study for this condition label.

  3. Most Sarcoma, Kaposi trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.

  4. Sarcoma, Kaposi research is mostly interventional.

    5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 22Phase 31

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2
Phase 3 1

Named interventions

Most-linked intervention names on Sarcoma, Kaposi records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Zidovudine Drug
3 trials
Vincristine sulfate Drug
2 trials
Bleomycin sulfate Drug
2 trials
Interferon alfa-2a Drug
1 trials
Interferon alfa-2b Drug
1 trials
Doxorubicin hydrochloride (liposomal) Drug
1 trials
Doxorubicin hydrochloride Drug
1 trials
Sargramostim Drug
1 trials

US sites by state

Facility locations filed on Sarcoma, Kaposi trials. A trial with sites in several states counts in each.

New York 4 trials
Massachusetts 3 trials
California 3 trials
Pennsylvania 2 trials
Ohio 2 trials
Maryland 2 trials
Louisiana 2 trials
Washington 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Sarcoma, Kaposi page

6 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sarcoma, Kaposi condition card totals 6 registered trials; most-linked intervention Zidovudine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.